Low RBC counts predict high on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention and treated with clopidogrel
Yours Sincerely
Qian Gu
Qin Wang
Rui Hua
Wenhao Zhang
Jianzhen Teng
Jiazheng Ma
Zhou Dong
Xiaoxuan Gong
Chunjian Li
Department of Cardiology,the First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China
摘要：Dear Editor,
Cardiovascular disease is the leading cause of deaths worldwide,with coronary artery disease (CAD)accounting for approximately 50％ of its mortality.Dual antiplatelet therapy,including aspirin and a P2Y12 inhibitor,is the most important treatment for CAD patients undergoing percutaneous coronary intervention (PCI) to prevent recurrent ischemic events and cardiac death. Clopidogrel is one of the commonly used P2Y12 inhibitors. However,up to 30％ of patients treated with a standard dose of clopidogrel present with high on-treatment platelet reactivity (HOPR),which is associated with the increased ischemic risks[1].
机标关键词：percutaneouspredictcountshighwithclopidogrelcoronaryintervention
分类号：R541.4(心脏、血管（循环系）疾病)
论文发表日期：2024-01-30
在线出版日期：2026-03-31（本平台首次上网日期，不代表文献的发表时间）
页数：6( 中插7,87-91 )